title: Role of Tamsulosin Therapy after Extracorporeal Shockwave Lithotripsy for Renal Stones: Randomized Controlled Trial.
abstract: BACKGROUND
  To evaluate the efficacy of adjunctive tamsulosin therapy after extracorporeal shockwave lithotripsy (SWL) for renal stones.
  
  
  METHODS
  This prospective study was conducted on patients who underwent single-session SWL for solitary renal stone less than 20 mm. Post-SWL, patients were randomly divided into 2 groups; the tamsulosin group (TG), received a daily dose of tamsulosin 0.4 mg, for a maximum of 12 weeks, with post-SWL traditional analgesia and control group (CG), received the traditional analgesia alone.
  
  
  RESULTS
  The study enrolled 271 patients and eventually only 249 (123 in TG and 126 in CG) completed the study. The overall stone free rate was 73.5%: 78.0% in TG and 69.0% in CG (p = 0.108). In TG, 8.1% of patients experienced at least one episode of acute renal/ureteral colic compared with 19.8% of controls (p = 0.008). The mean cumulative analgesia dosage per subject was 313 mg in TG and 346 mg in CG (p < 0.001). Overall, 14 patients developed steinstrasse and 6 of them (all in CG) needed urgent intervention (p = 0.031).
  
  
  CONCLUSIONS
  Daily tamsulosin therapy does not enhance the clearance of stone fragments but decreases the pain episodes, analgesia dosage and need for adjuvant intervention after SWL for renal stones.
authors.affiliation: Department of Urology, Al-Azhar University, Cairo, Egypt.
authors.forename: Abul-Fotouh
authors.initials: AF
authors.lastname: Ahmed
authors.forename: Essam
authors.initials: E
authors.lastname: Shalaby
authors.forename: Mohamed
authors.initials: M
authors.lastname: El-Feky
authors.forename: Ayman
authors.initials: A
authors.lastname: Kotb
authors.forename: Ebrahim
authors.initials: E
authors.lastname: Elsotohi
authors.forename: Mohamed
authors.initials: M
authors.lastname: El-Kholy
authors.forename: Ahmed
authors.initials: A
authors.lastname: Ragab
authors.forename: Emad
authors.initials: E
authors.lastname: Salem
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use*; D000328:Adult; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007669:Kidney Calculi / Q000188:drug therapy / Q000628:therapy*; D008096:Lithotripsy; D008297:Male; D011446:Prospective Studies; D013449:Sulfonamides / Q000627:therapeutic use*; D000077409:Tamsulosin
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D013449:Sulfonamides; D000077409:Tamsulosin